ClonOrgan

ClonOrgan is a biotechnology company that has been pioneering the future of organ transplantation since its establishment in 2005. The company's slogan, "Pioneering the future of organ transplantation with human-compatible organs grown from gene-edited pigs through a comprehensive R&D platform," encapsulates its groundbreaking approach. ClonOrgan focuses on xenotransplantation and has devised a method to humanize pig cells, thereby enabling the growth of organs compatible with human transplantation. The last investment of $6.97M Series A came from Royal Sea Capital on 03 September 2021. ClonOrgan offers a comprehensive R&D platform that spans from the cultivation of gene-edited pigs to preclinical testing and breeding. The company's mission is to address the severe shortage of organs for clinical transplantation and establish the future's organ production hub. Located in Chengdu, Sichuan, ClonOrgan is at the forefront of addressing this critical medical need. In the rapidly evolving fields of biotechnology and healthcare, ClonOrgan's innovative approach and recent investment from Royal Sea Capital demonstrate the confidence and potential in the company's vision to revolutionize organ transplantation.